Experience of using vaginal autoprobiotics in a patient with spontaneous triplet pregnancy with recurrent vaginal anaerobic dysbiosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance: The incidence of preterm birth associated with premature rupture of the membranes remains at a stable level in the world despite the development of new approaches to therapy and their standardization. The rupture of the membranes during pregnancy is known to be directly associated with anaerobic vaginal dysbiosis. Multiple pregnancy in women with vaginal dysbiosis almost always ends in preterm delivery of infants with extremely and very low birth weight. The existing approaches to the treatment of vaginal dysbiosis during pregnancy do not always show a 100% effectiveness; therefore, it is necessary to find new alternative ways to normalize the vaginal microbiota.

Case report: We present a clinical case of recurrent anaerobic vaginal dysbiosis in a pregnant woman with spontaneous triplet pregnancy who was prescribed vaginal autoprobiotics. The woman was examined and treated at Professor Bushtyreva Clinic, Rostov-on-Don, Russia. The prescription of vaginal autoprobiotics made it possible to normalize the state of the vaginal microbiota of the pregnant woman, obtain absolute normocenosis, avoid premature rupture of the membranes and deliver full-term infants in high-risk pregnancy.

Conclusion: The prescription of vaginal autoprobiotics as therapy for anaerobic dysbiosis is a personalized and safe method of treatment, since autoprobiotics represent a woman’s own beneficial lactobacillus vaginal microflora that is genetically close and that does not cause rejection reactions. It is necessary to carry out further extensive studies on the effectiveness of vaginal autoprobiotics in pregnancy for the possible popularization of this technique.

Full Text

Restricted Access

About the authors

Viktoriya V. Barinova

Rostov State Medical University, Ministry of Health of Russia; Professor Bushtyreva Clinic

Email: victoria-barinova@yandex.ru
ORCID iD: 0000-0002-8584-7096
ResearcherId: AAH-3314-2019

PhD, Assistant of the Department of Obstetrics and Gynecology No. 1; Head of the Obstetric Department

Russian Federation, Rostov-on-Don; Rostov-on-Don

Irina O. Bushtyreva

Professor Bushtyreva Clinic

Email: kio4@mail.ru

Dr. Med. Sci., Professor, Director

Russian Federation, Rostov-on-Don

Natalya B. Kuznetsova

Rostov State Medical University, Ministry of Health of Russia; Professor Bushtyreva Clinic

Author for correspondence.
Email: lauranb@inbox.ru

Dr. Med. Sci., Professor of the Simulation Training Center; Chief Physician

Russian Federation, Rostov-on-Don; Rostov-on-Don

Alexander N. Suvorov

Saint Petersburg State University

Email: suvorov.an@iemspb.ru

Dr. Med. Sci., Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Molecular Microbiology

Russian Federation, Saint Petersburg

Tatyana L. Botasheva

Rostov State Medical University, Ministry of Health of Russia

Email: t_botasheva@mail.ru
Scopus Author ID: 55531205100
ResearcherId: HKE-0537-2023

Dr. Med. Sci., Professor, Chief Researcher of the Obstetrics and Gynecology Department

Russian Federation, Rostov-on-Don

References

  1. Gupta S., Allen-Vercoe E., Petrof E.O. Fecal microbiota transplantation: in perspective. Therap. Adv. Gastroenterol. 2016; 9(2): 229-39. https://dx.doi.org/10.1177/1756283X15607414.
  2. Vuotto C., Longo F., Donelli G. Probiotics to counteract biofilm-associated infections: promising and conflicting data. Int. J. Oral Sci. 2014; 6(4): 189-94. https://dx.doi.org/10.1038/ijos.2014.52.
  3. Suvorov A., Karaseva A., Kotyleva M., Kondratenko Y., Lavrenova N., Korobeynikov A. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol. 2018; 9: 1869. https://dx.doi.org/10.3389/fmicb.2018.01869.
  4. Mannik J., Driessen R., Galajda P. Bacterial growth and motility in sub-micron constrictions. Proc.Natl. Acad. Sci. U.S.A. 2009; 106 (35): 14861-6. https://dx.doi.org/10.1073/pnas.0907542106.
  5. Ермоленко Е.И., Лапидус А.Л., Суворов А.Н. Оптимизация микробной терапии дисбиотических состояний посредством аутопробиотиков. В кн.: Обеспечение эпидемиологического благополучия: вызовы и решения: Материалы XI съезда ВНПОЭМП Москва, 16-17 ноября 2017г. М.: ФБУН НИИ эпидемиологии и микробиологии имени Пастера; 2017. 429c. [Ermolenko E.I., Lapidus A.L., Suvorov A.N. Optimization of microbial therapy of dysbiotic states through autobrobiotics. In: Ensuring epidemiological well-being: challenges and solutions: materials of the XI Congress of VNPOEMP Moscow, November 16-17, 2017. Moscow: Research Institute of Epidemiology and Microbiology named after Pasteur; 2017. 429p. (in Russian)].
  6. Ильин В.К., Суворов А.Н., Кирюхина Н.В., Усанова Н.А., Старкова Л.В., Бояринцев В.В., Карасева А.Б. Аутопробиотики как средство профилактики инфекционно-воспалительных заболеваний у человека в искусственной среде обитания. Вестник РАМН. 2013; 2: 56-62. [Il’in V.K., Suvorov A.N., Kiryukhina N.V., Usanova N.A., Starkova L.V., Boyarintsev V.V., Karaseva A.B. Autochthonous probiotics in prevention of infectious and inflammatory diseases of a human in the altered habitats. Bulletin of the Russian Academy of Medical Sciences. 2013; (2): 56-62. (in Russian)].
  7. Симаненков В.И., Соловьева О.И., Сундукова З.Р., Суворов А.Н., Цапиева А.Н. Аутопробиотическая профилактика и лечение дисбиотических расстройств. Методические рекомендации. СПб.; 2020. 24с. [Simanenkov V.I., Solovyova O.I., Sundukova Z.R., Suvorov A.N., Tsapieva A.N. Auto-probiotic prevention and treatment of dysbiotic disorders: method. recommendations. St. Petersburg; 2020. 24p. (in Russian)].
  8. Sanders M.E., Akkermans L.M.A., Haller D., Hammerman C., Heimbach J., Hörmannsperger G. et al. Safety assessment of probiotics for human use. Gut Microbes. 2010; 1(3): 164-85. https://dx.doi.org/10.4161/gmic.1.3.12127.
  9. Hanlon P.R., Frestedt J., Magurany K. GRAS from the ground up: review of the interim pilot program for GRAS notification. Food Chem. Toxicol. 2017; 105: 140-50. https://dx.doi.org/10.1016/j.fct.2017.03.064.
  10. Wessels S., Axelsson L., Hansen E.B., De Vuyst L., Laulund S., Lähteenmäki L. et al. The lactic acid bacteria, the food chain, and their regulation. Trends Food Sci. Technol. 2004; 15(10): 498-505. https://dx.doi.org/10.1016/ j.tifs.2004.03.003.
  11. Tsapieva A., Duplik N., Suvorov A. Structure of plantaricin locus of Lactobacillus plantarum 8P-A3. Benef Microbes. 2011; 2(4): 255-61. https://dx.doi.org/10.3920/BM2011.0030.
  12. Ravel J., Gajer P., Abdo Z., Schneider G.M., Koenig S.S.K., McCulle S.L. et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U.S.A. 2011;108(Suppl. 1): 4680-7. https://dx.doi.org/10.1073/pnas.1002611107.
  13. France M.T., Ma B., Gajer P., Brown S., Humphrys M.S., Holm J.B. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome. 2020; 8(1): 166. https://dx.doi.org/10.1186/s40168-020-00934-6.
  14. Pascual L.M., Daniele M.B., Ruiz F., Giordiano W., Pajaro C., Barberis L. Lactobacillus rhamnosus L60, a potential probiotic isolated from the human vagina. J. Gen. Appl. Microbiol. 2008; 54(3): 141-8. https://dx.doi.org/10.2323/jgam.54.141.
  15. Ruiz F.O., Gerbaldo G., Asurmendi P., Pascual L.M., Giordano W., Barberis I.L. Antimicrobial activity, inhibition of urogenital pathogens, and synergistic interactions between lactobacillus strains. Curr. Microbiol. 2009; 59(5): 497-501. https://dx.doi.org/10.1007/s00284-009-9465-0.
  16. Gardiner G.E., Heinemann C., Bruce A.W., Beuerman D., Reid G. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin. Diagn. Lab. Immunol. 2002; 9(1): 92-6. https://dx.doi.org/10.1128/cdli.9.1.92-96.2002.
  17. Begovic J., Huys G., Mayo B., D'Haene K., Florez A.B., Lozo J. et al. Human vaginal Lactobacillus rhamnosus harbor mutation in 23S rRNA associated with erythromycin resistance. Res. Microbiol. 2009; 160(6): 421-6. https://dx.doi.org/10.1016/j.resmic.2009.07.005.
  18. Ермоленко Е.И., Котылева М.П., Лавренова Н.С., Карасева А.Б., Цапиева А.Н., Алехина Г.Г. и др. Новая стратегия выбора аутопробиотиков. Гастроэнтерология Санкт-Петербурга. 2020; 1-2: 81-2. [Ermolenko E.I., Kotyleva M.P., Lavrenova N.S., Karaseva AB, Tsapieva A.N., Alekhina G.G. et al. A new strategy for electing autoprobiotics. Gastroenterology of St. Petersburg. 2020; (1-2): 81-2. (in Russian)].
  19. Соловьева О.И., Симаненков В.И., Суворов А.Н., Ермоленко Е.И., Шумихина И.А., Свиридов Д.А. Использование пробиотиков и аутопробиотиков в лечении синдрома раздраженной толстой кишки. Экспериментальная и клиническая гастроэнтерология. 2017; 7: 115-20. [Solov’eva O.I., Simanenkov V.I., Suvorov A.N., Ermolenko E.I., Shumihina I.A., Sviridov D.A. The use of probiotics and autoprobiotics in the treatment of irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2017; (7) :115-20. (in Russian)].
  20. Соловьева О.И., Шумихина И.А., Сундукова З.Р. Свой свояка видит издалека, или аутопробиотическая терапия СРК. Гастроэнтерология Санкт-Петербурга. 2020; 1-2: 91-2. [Solovyova O.I., Shumikhina I.A., Sundukova Z.R. He sees his brother-in-law from afar, or autoprobiotic therapy for IBS. Gastroenterology of St. Petersburg. 2020; (1-2): 91-2. (in Russian)].
  21. Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Крамская Т.А., Карасева А.Б., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017; 7: 89-96. [Ermolenko E.I., Erofeev N.P., Zacharova L.B., Pariyskaya E.N., Kotyleva M.P., Kramskaya T.A., Karaseva A.B., Suvorov A.N. Features of microbiota content and intestinal motility after the correction of experimental dysbiosis with probiotic and autoprobiotic enterococci. Experimental and Clinical Gastroenterology. 2017; (7): 89-96. (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Femoflor-16 test results at 7 weeks and 12 weeks of gestation respectively in patient N. with triplets

Download (362KB)
Indexing metadata
3. Fig. 2. Femoflor-16 test results at 19 weeks 3 days of gestation in patient N. with triplets

Download (187KB)
Indexing metadata
4. Fig. 3. Results of 16s rRNA sequencing of vaginal secretion from patient N. with triplets at 20 weeks of gestation

Download (106KB)
Indexing metadata
5. Fig. 4. Results of the femoflor-16 test in patient N. with triplets at 28 weeks' gestation before the start of therapy with vaginal autoprobiotics

Download (178KB)
Indexing metadata
6. Fig. 5. Femoflor-16 test results at 36-37 weeks of gestation in patient N. with triplets

Download (173KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies